Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Array
Free
Posted in: Autologous, CAR-T, CD19 Mar 15 | 2024Obe-cel MAA Submitted to the EMA; Nucleus Manufacturing Facility Ready for Obe-cel Launch; Obe-cel’s Trial in SLE and AUTO6NG’s Study in Pediatric Glioblastoma Initiated; Autolus Q4 2023 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Feb 07 | 2024Yescarta Revenue Decreases while Tecartus Sales Hold; ZUMA-24 Readout Delayed to H2 2024; Anito-cel's Trial in Early Line MM to Initiate in H2 2024; Gilead’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, TCR Feb 02 | 20242seventy bio to Focus Exclusively on Abecma; Sells Pipeline to Regeneron; Afami-Cel BLA Granted Priority ReviewAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 31 | 2024Breyanzi Regulatory Applications for R/R FL and R/R MCL Accepted in the US and JapanAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 26 | 2024CHMP Adopts Positive Opinion for Abecma in ≥3L MM; January CHMP HighlightsAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jan 24 | 2024Sales of Carvykti Continue to Grow; FDA and EMA Advisory Committees Will Review Carvykti Applications for Early MM; JNJ Considers Entering in Autoimmune Diseases; JNJ’s Q4 2023 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jan 22 | 2024Obe-cel BLA in R/R B-ALL Accepted Although No Priority Review Was GrantedAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Jan 11 | 2024JPM 2024 Analysis Day 3: AllogeneAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jan 10 | 2024JPM 2024 Analysis Day 2: Legend, AstraZeneca, and BioNTechAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Dec 14 | 2023Uncertainty around OS Benefit Induced by Abecma in 3 – 5L MM; A MAIC Analysis Supports Carvykti’s Superiority versus Abecma in Early Line MM; ASH 2023 Analysis 7Access Free Blast
Free
Posted in: Autologous, CAR-T Nov 14 | 2023Thoughts on Novartis’s Agreement with LegendAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T Nov 13 | 2023Roche Collaboration Milestones and Payments Accelerated; P-MUC1C-ALLO1's Clinical Update Postponed to H1 2024; Poseida’s Q3 2023 Earnings SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T Nov 07 | 2023Lyell and CRISPR Tx Present Novel CAR-Ts in Solid Tumors; SITC 2023 Analysis 2Access Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Nov 06 | 2023Carisma Tx Shows Initial Results from its Collaboration with Moderna; AstraZeneca Presents AZD6422’s Preclinical Development in Gastrointestinal Cancers and a Synergistic Combination of AZD074 with Enzalutamide in Prostate Cancer; SITC 2023 Analysis 1Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Nov 06 | 2023Could Abecma Receive a CHMP Positive Opinion this Week?; November’s CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, TCR Nov 03 | 2023Adaptimmune Presents Positive Lete-cel and Afami-cel Data in SS and MRCLSAccess Free BlastFree
Posted in: Autologous, CAR-T Nov 02 | 2023Kite to Collaborate with Epic Bio to Develop New Therapies for CancerAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 25 | 2023Kymriah's Revenue Continues to Decrease; No Updates on Cell Therapy Programs; Novartis’s Q3 2023 Earnings Call SummaryAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.